Keita Takeda1, Hideaki Nagai2, Maho Suzukawa3, Ryo Sekiguchi4, Shunsuke Akashi5, Ryota Sato6, Osamu Narumoto7, Masahiro Kawashima8, Junko Suzuki9, Nobuharu Ohshima10, Akira Yamane11, Atsuhisa Tamura12, Hirotoshi Matsui13, Shigeto Tohma14. 1. Center for Pulmonary Diseases, National Hospital Organization Tokyo National Hospital; Department of Basic Mycobacteriology, Graduate School of Biomedical Science, Nagasaki University. Electronic address: takeda.keita.ax@mail.hosp.go.jp. 2. Center for Pulmonary Diseases, National Hospital Organization Tokyo National Hospital. Electronic address: hnagai-tokyohosp@umin.ac.jp. 3. Clinical Research Center, National Hospital Organization Tokyo National Hospital. Electronic address: fueta-tky@umin.net. 4. Center for Pulmonary Diseases, National Hospital Organization Tokyo National Hospital. Electronic address: s_ryo_janne@outlook.jp. 5. Center for Pulmonary Diseases, National Hospital Organization Tokyo National Hospital. Electronic address: akashi.shunsuke.gs@mail.hosp.go.jp. 6. Center for Pulmonary Diseases, National Hospital Organization Tokyo National Hospital. Electronic address: sato.ryota.tq@mail.hosp.go.jp. 7. Center for Pulmonary Diseases, National Hospital Organization Tokyo National Hospital. Electronic address: narumoto.osamu.ku@mail.hosp.go.jp. 8. Center for Pulmonary Diseases, National Hospital Organization Tokyo National Hospital. Electronic address: kawashima.masahiro.wr@mail.hosp.go.jp. 9. Center for Pulmonary Diseases, National Hospital Organization Tokyo National Hospital. Electronic address: suzuki.junko.fv@mail.hosp.go.jp. 10. Center for Pulmonary Diseases, National Hospital Organization Tokyo National Hospital. Electronic address: ooshima.nobuharu.bp@mail.hosp.go.jp. 11. Center for Pulmonary Diseases, National Hospital Organization Tokyo National Hospital. Electronic address: yamane.akira.yu@mail.hosp.go.jp. 12. Center for Pulmonary Diseases, National Hospital Organization Tokyo National Hospital. Electronic address: tamura.atsuhisa.py@mail.hosp.go.jp. 13. Center for Pulmonary Diseases, National Hospital Organization Tokyo National Hospital. Electronic address: matsui.hirotoshi.sa@mail.hosp.go.jp. 14. Asthma Allergy and Rheumatology Center, National Hospital Organization Tokyo National Hospital. Electronic address: touma.shigeto.jy@mail.hosp.go.jp.
Abstract
OBJECTIVES: This study evaluated the efficacy of the following interferon (IFN)-γ release assays (IGRAs): QuantiFERON-TB Gold Plus (QFT-Plus), QFT-Gold In-Tube (QFT-GIT), and T-SPOT. TB (T-SPOT) with the quantitative values of IFN-γ response. METHODS: Blood samples were collected from patients with active tuberculosis (TB), latent TB infection (LTBI), individuals with previous TB infection, and healthy volunteers enrolled between May 2017 and June 2018. RESULTS: IGRAs results were analyzed in 175 subjects (76 had active TB, 14 had LTBI, 35 had prior TB infection, and 50 were healthy). QFT-Plus and QFT-GIT revealed equal efficacy for IFN-γ values, and the IFN-γ response in QFTs tended to increase with the spot counts in T-SPOT, with similar high sensitivities (approximately 90%) in the active TB group. The test concordance of two of three IGRAs was optimal among all subjects (κ coefficients: 0.82-0.96). Additionally, the median quantitative values of IFN-γ with QFT-Plus and QFT-GIT were higher in the active TB group than in the LTBI and previous TB groups. CONCLUSION: Three IGRAs showed equivalent efficacy with high sensitivities and higher IFN-γ response in active TB group than that in non-active TB group.
OBJECTIVES: This study evaluated the efficacy of the following interferon (IFN)-γ release assays (IGRAs): QuantiFERON-TB Gold Plus (QFT-Plus), QFT-Gold In-Tube (QFT-GIT), and T-SPOT. TB (T-SPOT) with the quantitative values of IFN-γ response. METHODS: Blood samples were collected from patients with active tuberculosis (TB), latent TB infection (LTBI), individuals with previous TB infection, and healthy volunteers enrolled between May 2017 and June 2018. RESULTS: IGRAs results were analyzed in 175 subjects (76 had active TB, 14 had LTBI, 35 had prior TB infection, and 50 were healthy). QFT-Plus and QFT-GIT revealed equal efficacy for IFN-γ values, and the IFN-γ response in QFTs tended to increase with the spot counts in T-SPOT, with similar high sensitivities (approximately 90%) in the active TB group. The test concordance of two of three IGRAs was optimal among all subjects (κ coefficients: 0.82-0.96). Additionally, the median quantitative values of IFN-γ with QFT-Plus and QFT-GIT were higher in the active TB group than in the LTBI and previous TB groups. CONCLUSION: Three IGRAs showed equivalent efficacy with high sensitivities and higher IFN-γ response in active TB group than that in non-active TB group.